Molagri
New accelerator entry · 2026-06-29 · the record
MentionFox
Molagri develops safer, more effective pesticides for agriculture. We design biopesticides that hit a precise molecular target unique to pest insects, knocking out pests while sparing pollinators, beneficial insects, and the wider ecosystem.
Molagri is a Y Combinator company in the Summer 2026 batch. Its directory entry describes it as: Resistance free pesticides. The founders listed are Zaky Hassan (Founder/CEO), Min Jin (Founder) (Y Combinator directory entry, June 29, 2026).
Sell to companies like these? Paste your website and see 10 with a filed reason to buy this month. Free.
Opens in a new tab. No signup.
New accelerator entry · 2026-06-29 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Molagri.
Free to see. No signup.
We'll show it in your MentionFox inbox when Molagri raises, hires or launches. No email unless you switch it on.
Watch Molagri →Get the full cited report on Molagri
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Molagri: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Molagri develops safer, more effective pesticides for agriculture. We design biopesticides that hit a precise molecular target unique to pest insects, knocking out pests while sparing pollinators, beneficial insects, and the wider ecosystem. By modeling how pests are likely to evolve, we stay a step ahead of resistance, keeping our products effective against the pests of today and tomorrow. The higher efficacy and biobased production will also contribute to emissions reductions in both manufacturing and field use. Our founders are PhD lab mates from the University of Toronto who have worked together for six years and published in Nature Communications and Nature Microbiology.
Read from the page's own HTML and response headers on 10 September 2026, at https://molagri.com/. Each badge matched a string the site serves about itself — hover one to see which. Nothing here is a traffic, ranking or revenue figure: those cannot be read off a page and are not claimed.
Checked away from the directory entry. What is below does not come from the company's Y Combinator page.
Molagri engineers biology into precise, biopesticide-based crop protection — better tools for the people moving agriculture forward.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Zaky is a protein biochemist and viral structural biologist who has characterized mechanisms of antibody neutralization in human pathogenic coronaviruses. He has an undergraduate degree in Biochemistry (Honours BSc) and graduate training in Biochemistry (PhD candidate) from the University of Toronto. He was awarded $130K+ in fellowships, and published twice in Nature Communications. Zaky previously founded a non-profit, raised $1M+ in grants and operated programming for 1000+ youth in Toronto.
Min is a viral structural biologist and protein biochemist, and the current world record holder for the highest resolution structure of a coronavirus spike protein in the Protein Data Bank (1.68 Å). She has an undergraduate degree in Biophysics (Honours BSc) and graduate training in Biochemistry (PhD candidate) from the University of Toronto and she has published in Nature Microbiology and Nature Communications.
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Molagri: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Molagri covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist MolagriYou get an alert in MentionFox the next time this company shows up.
If you're behind Molagri: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry, and from the company's own site, read directly on 2026-09-06 (molagri.com).
Each opens in a new tab, filled in for Molagri. With no account yet, you sign up free and land on the result.

https://mentionfox.com/funding/yc-molagri